Madrigal Pharma Presents Phase 3 MAESTRO-NASH Data During the Opening General Session of the EASL Congress
Portfolio Pulse from Benzinga Newsdesk
Madrigal Pharmaceuticals (NASDAQ:MDGL) presents resmetirom Phase 3 MAESTRO-NASH data at the European Association for the Study of the Liver Congress (EASL 2023).
June 22, 2023 | 7:31 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Madrigal Pharmaceuticals presents positive Phase 3 MAESTRO-NASH data at EASL 2023, potentially boosting its stock price.
The presentation of positive Phase 3 MAESTRO-NASH data at EASL 2023 indicates that Madrigal Pharmaceuticals' resmetirom is progressing well in clinical trials. This could lead to increased investor confidence and a potential boost in the stock price in the short term.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100